← boardnext 2026-12
TLTFF
Theralase® Technologies Inc.distress 4/10 · elevated risk$0.18-3%today-36% from 52w high
Lead: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Revenue
pre-revenue
Liquidity
$1M
Runway
0.3 yrs
Shares 1y
—
Price & events
+2.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
+2.8%
1W
+8.8%
1M
-26.0%
3M
+2.8%
6M
+23.3%
1Y
+42.3%
2Y
-7.5%
5Y
+15.6%
All
Overview
- Volume
- 1.50K
- 52 Week Range
- $0.11 – $0.29
- Float Shares
- 276.45M
- % Held by Insiders
- 8.40%
- % Held by Institutions
- 0.00%
- RVOL
- 0.02x
- Beta
- 0.59
Pipeline stages · 1 programs
Ruvidar® (TLD-1433) bladder infusion and PDT
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | Ruvidar® (TLD-1433) bladder infusion and PDT | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-26Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
- none identified
Recent news
- 2026-07-23EBITDA per share of Theralase Technologies Inc Warrant 2026-20.05.2031 on Theralase Tech – TSXV:TLT.WT - TradingView
- 2026-07-13Price to book forward of Theralase Technologies Inc Warrant 2026-20.05.2031 on Theralase Tech – NEO:TLT.WT - TradingView
- 2026-06-03Theralase(R) Lists Warrants on the TSXV - TMX Newsfile
- 2026-05-20Theralase(R) Closes C$4.8 Million Offering - TMX Newsfile
- 2026-05-07TSXV:TLT Forum Post | knoxt-36993559 | TOP BULLBOARDS , We are # 1 . | Theralase Technologies Inc - Stockhouse
- 2026-05-05Theralase(R) Announces $4 Million Brokered LIFE Offering - TMX Newsfile
- 2026-05-04Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update - TMX Newsfile
- 2026-04-13Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study - TMX Newsfile
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.